About Dr Lionel Hebbard

Dr Hebbard is a PhD scientist with a passionate interest in cancer biology, angiogenesis and in tissue responses to injury.

Dr Lionel Hebbard is a scientist, employed as a Research Fellow at the Storr Liver Unit, Westmead Millennium Institute. He completed his PhD in Germany and for his postdoctoral time he worked at the University Hospital Zurich, Switzerland and the Burnham Institute for Medical Research, La Jolla, USA. He has recently returned from the USA to continue his research in Australia. His current research focuses on the role of adiponectin and its receptors in cancer, angiogenesis and in liver injury and fibrosis. His current work employs a combination of mouse models, molecular biology, cell biology and histology. The work will be based in the Storr Liver Unit which has the advantage of being able to draw on patient data and samples to further support experimental data.

Dr Hebbard completed his PhD in 1999 at the Institute for Genetics, Forschungszentrum Karlsruhe, Germany, under the guidance of Professors Peter Herrlich and Jonathan Sleeman. His doctoral studies dealt with the role of CD44 in mouse and rat mammary gland development (J Cell Sci.,113, 2619-30; 2000). In his first Postdoctoral position at the University Hospital Zurich, Switzerland under Professor Roman Klemenz, he was part of the team who found T-cadherin to be upregulated on the vasculature of mouse tumours (Cancer Research, 60, 4682-4688, 200). In 2001 he moved to the Burnham Institute of Medical Research in La Jolla, California, to continue his work with Professor Barbara Ranscht. There Dr Hebbard characterized the function of T-cadherin in angiogenesis and mammary cancer (Cancer Research, 64, 169-179, 2004). He characterized knock-out T-cadherin mice and created transgenic mice and used them to functionally determine that the interaction of adiponectin and T-cadherin is an important mediator of angiogenesis and mammary tumour growth and progression (Cancer Res 68, 1407-16, 2008, Clin Cancer Res, In Press, 2009).
To learn about cancer stem cells Dr Hebbard worked with Professor Robert Oshima at the Burnham Institute from February 2007 to May 2008. There, using mouse models he tested new chemical inhibitors and elucidated the role of MELK (mammalian embryonic leucine kinase) in mouse mammary mammary models.

AWARDS AND HONOURS * Fellowship from the Royal Australian College of Physicians for MPhil studies (1992-3). * PhD Fellowship for doctoral work from the Forschungszentrum Karlsruhe, Germany (1995-99). * Travel fellowship from the Keystone Conference Foundation (2004). * Career development award from the Fishman Fund (2005).

Selected publications

For a comprehensive list of Dr Hebbard's publicatons, please visit his Sydney Medical School profile page.